SanegeneBio

Company Deals

SanegeneBio Partners with Genentech on RNAi Therapy in $1.7B Deal

Fineline Cube Feb 3, 2026

SanegeneBio, a Suzhou‑based RNA interference (RNAi) therapeutics developer, announced a global partnership with Genentech, a...

Company Drug

SanegeneBio’s INHBE siRNA Wins China IND for Obesity as First RNAi Target

Fineline Cube Dec 21, 2025

SanegeneBio, a clinical‑stage RNAi therapeutics company, announced that China’s National Medical Products Administration (NMPA) approved...

Company Deals

SanegeneBio & Eli Lilly Sign Global Partnership to Advance RNAi Therapies for Metabolic Diseases

Fineline Cube Nov 10, 2025

SanegeneBio, a biotechnology company specializing in RNAi therapeutics, today announced a global research collaboration and...

Company Deals

SanegeneBio Secures Over USD 80 Million in Series A+ Funding to Advance RNAi Therapeutics

Fineline Cube Dec 4, 2023

SanegeneBio, a Suzhou-based developer of RNA interference (RNAi) therapeutics, has successfully raised over USD 80...

Company Deals

Insight Lifetech Debuts on Shanghai STAR Market with $3 Billion Valuation, Breaking Import Monopoly in Cardiovascular Imaging

Company Drug

Fosun Pharma’s Fumaining Wins Priority Review for NF1 Adult Indication in China

Company Drug

Hengrui Pharma Secures NMPA Nod for SHR-1894 Atopic Dermatitis Trial

Company Drug

Akeso’s Ivonescimab Secures Fifth Breakthrough Therapy Designation for Biliary Tract Cancer in China